Loading...
XSTOSENZA
Market cap17mUSD
Dec 23, Last price  
6.70SEK
1D
2.29%
1Q
-4.29%
IPO
-83.17%
Name

SenzaGen AB

Chart & Performance

D1W1MN
XSTO:SENZA chart
P/E
—
P/S
3.96
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
9.27%
Rev. gr., 5y
90.32%
Revenues
50m
+19.39%
1,624,0001,748,000498,0001,153,0001,997,0002,724,0007,958,00015,422,00041,770,00049,870,000
Net income
-22m
L-11.30%
262,000-2,857,000-8,942,000-12,994,000-16,090,000-50,237,000-27,315,000-31,346,000-24,912,000-22,097,000
CFO
-16m
L+2.38%
1,042,999-6,281,000-9,692,000-11,646,000-23,212,000-31,081,000-29,376,000-20,980,000-16,071,000-16,453,000

Profile

SenzaGen AB develops, performs, and sells non-animal tests for assessing a substance's allergenicity. The company offers genomic allergen rapid detection (GARD)skin, an in vitro test to identify potential chemical skin sensitizers; GARDpotency, an in vitro add-on test to GARDskin for potency classification; GARDskin Dose-response, an in vitro test for quantitative skin sensitizing potency assessment of chemicals; and GARDair, an in vitro test for identifying chemical respiratory sensitizers, as well as GARDskin medical device, an in vitro skin sensitization testing for medical devices and solid materials. It also provides irritation and corrosion testing services. The company offers services through license partners and distributors. It has a collaboration agreement with the Research Institute for Fragrance Materials to develop tests for photosensitization. The company was incorporated in 2010 and is headquartered in Lund, Sweden.
URL
https://senzagen.com/
IPO date
Sep 21, 2017
Employees
35
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
49,870
19.39%
41,770
170.85%
15,422
93.79%
Cost of revenue
64,610
62,446
46,627
Unusual Expense (Income)
NOPBT
(14,740)
(20,676)
(31,205)
NOPBT Margin
Operating Taxes
121
(50)
(19)
Tax Rate
NOPAT
(14,861)
(20,626)
(31,186)
Net income
(22,097)
-11.30%
(24,912)
-20.53%
(31,346)
14.76%
Dividends
Dividend yield
Proceeds from repurchase of equity
(42)
29,664
BB yield
0.01%
-12.33%
Debt
Debt current
(99)
(1,546)
Long-term debt
1,673
1,207
714
Deferred revenue
Other long-term liabilities
(1,207)
(714)
Net debt
(15,951)
(38,868)
(69,996)
Cash flow
Cash from operating activities
(16,453)
(16,071)
(20,980)
CAPEX
(129)
(2,589)
(2,665)
Cash from investing activities
(6,082)
(13,437)
(26,555)
Cash from financing activities
147
31
27,290
FCF
(14,097)
(19,971)
(31,334)
Balance
Cash
17,624
39,976
69,164
Long term investments
Excess cash
15,130
37,888
68,393
Stockholders' equity
67,553
88,780
107,504
Invested Capital
54,150
52,510
40,578
ROIC
ROCE
EV
Common stock shares outstanding
24,188
24,085
24,065
Price
7.28
-39.59%
12.05
20.50%
10.00
-23.66%
Market cap
176,089
-39.33%
290,230
20.60%
240,650
-13.99%
EV
160,138
251,362
170,654
EBITDA
(6,554)
(11,256)
(26,937)
EV/EBITDA
Interest
37
46
19
Interest/NOPBT